Atara Biotherapeutics, Inc. 10-Q

Item 5. Other Information None. 67 Item 6. Ex hibits Exhibit Incorporated by Reference Filed No. Description of Exhibit Form File No. Exhibit Filing Date Herewith 3.1 Amended and Restated Certificate of Incorporation of Atara Biotherapeutics, Inc. S-1 333-196936 3.2 6/20/2014 3.2 Amended and Restated Bylaws of Atara Biotherapeutics, Inc. S-1 333-196936 3.4 6/20/2014 10.1+ Deed of Amendment Number 1 to Third Amended and Restated License Agreement dated April 21, 2021 X 31.1 Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 31.2 Certification by Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 X 32.1(1) Certifications of Chief Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. X 104 The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in Inline XBRL. X + Portions of this exhibit have been omitted as being both (i) not material and (ii) the type of information that the registrant treats as private or confidential. (1) The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. 68 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Atara Biotherapeutics, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: August 9, 2021 By: /s/ Pascal Touchon Pascal Touchon President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) By: /s/ Utpal Koppikar Utpal Koppikar Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) 69